Skip to main content

Advertisement

SpringerLink
Log in

Low-dose intra-venous cyclophosphamide therapy in a patient with neurological complications of Behçet’s disease

  • Case Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Behçet’s disease (BD) is a chronic relapsing–remitting inflammatory disorder of unknown origin, affecting multiple organs. Neurological involvement is one of the most devastating manifestations of BD and may be fatal. We report a 36-year-old woman with neuro-Behçet who was treated with low-dose pulse cyclophosphamide (St. Thomas’ protocol) and methylprednisolone, with almost complete clinical remission.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Abbreviations

BD:

Behçet’s disease

CNS:

central nervous system

CYC:

cyclophosphamide

References

  1. Kocer N, Islak C, Siva A et al (1999) CNS involvement in neuro-Behçet’s syndrome: an MR study. AJNR Am J Neuroradiol 20:1015–1024

    PubMed  CAS  Google Scholar 

  2. Al-Araji A, Sharquie K, Al-Rawi Z (2003) Prevalence and patterns of neurological involvement in Behçet’s disease: a prospective study from Iraq. J Neurosurg Psychiatry 74:608–613

    Article  CAS  Google Scholar 

  3. The International Study Group for Behçet’s Disease (1992) Evaluation of diagnostic (“classification”) criteria in Behçet’s disease: towards internationally agreed criteria. Br J Rheumatol 31:299–308

    Article  Google Scholar 

  4. Tranel D (2005) On the use of neuropsychology to diagnose brain damage and study brain–behavior relationships: a comment on Luria. Cortex 41:259–262

    PubMed  Google Scholar 

  5. Crum RM, Anthony JC, Bassett SS, Folstein MF (1993) Population-based norms form Mini-Mental State Examination by age and educational level. JAMA 269:2386–2391

    Article  PubMed  CAS  Google Scholar 

  6. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E et al (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis. Arthritis Rheum 50:3934–3940

    Article  PubMed  Google Scholar 

  7. Gül A, Hajeer AH, Worthington J, Ollier B, Silman AJ (2001) Linkage mapping of a novel susceptibility locus for Behçet disease to chromosome 6p 22–23. Arthritis Rheum 44:239–241

    Article  PubMed  Google Scholar 

  8. Kidd D, Steuer A, Denman AM, Rudge P (1999) Neurological complication of Behçet’s Syndrome. Brain 122:2183–2194

    Article  PubMed  Google Scholar 

  9. Akman-Demir G, Serdarouglu P, Tacsi B, for the Neuro-Behçet Study Group (1999) Clinical patterns of neurological involvement in Behçet’s disease: evaluation of 200 patients. Brain 122:2171–2181

    Article  PubMed  Google Scholar 

  10. Pipitone N, Olivieri I, Cantini F, Triolo G, Salvarini C (2006) New approaches in the treatment of Adamantiades–Behcet’s disease. Curr Opin Rheumatol 18:3–9

    Article  PubMed  CAS  Google Scholar 

  11. Sangle S, Graham GRV, D’Cruz DP (2005) Infliximab in the management of resistant systemic vasculitis: poor response and significant adverse effects. Arthritis Rheum 52(Suppl 9):S 652

    Google Scholar 

  12. Boumpas DT, Austin HA, Vaugham EM, Yarboro CH et al (1993) Risk for sustained amenorrhoea in patients with systemic lupus erythematous receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 119:366–369

    PubMed  CAS  Google Scholar 

  13. Martin-Suarez, D’Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GR (1997) Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 56:481–487

    Article  PubMed  CAS  Google Scholar 

  14. Houssiau FA, Vascocelos C, D’Cruz D, Sebastiani GD, Garrido Ed Ede R et al (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46:2121–2131

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lupus Research Unit, The Rayne Institute, Lambeth Wing, St. Thomas’ Hospital, London, SE1 7EH, UK

    N. Melillo, S. Sangle & D. P. D’Cruz

  2. Ophthalmology Department, Guy’s and St. Thomas’ Hospital, London, UK

    M. R. Stanford

  3. Neurology Department, Guy’s and St. Thomas’ Hospital, London, UK

    T. C. Andrews

Authors
  1. N. Melillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Sangle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. R. Stanford
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. C. Andrews
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D. P. D’Cruz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D. P. D’Cruz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Melillo, N., Sangle, S., Stanford, M.R. et al. Low-dose intra-venous cyclophosphamide therapy in a patient with neurological complications of Behçet’s disease. Clin Rheumatol 26, 1365–1367 (2007). https://doi.org/10.1007/s10067-006-0385-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-006-0385-0

Keywords

Search

Navigation